Next time you lose your car keys and enlist the family to help you search, try a little experiment. After your spouse searches an area, go and look in the same place. It will likely feel strange, even irritating to both of you – and that?s because you may be fighting an ancient, hard-wired, human behaviour pattern.
A unique study by researchers at the University of York and Hull York Medical School has confirmed a link between depression and low levels of folate, a vitamin which comes from vegetables.
The increased incidence of chronic conditions among American children predicts serious strains on health care and social welfare systems in the future, caution investigators from Massachusetts General Hospital and Harvard School of Public Health.
The findings of a new rat study conducted by Italy?s Ramazzini Institute are contradictory to the extensive scientific research and regulatory reviews conducted on aspartame. The U.S. Food & Drug Administration (FDA) has stated they are not recommending any changes in the use of aspartame.
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) announced study results comparing treatment with BYETTA(R) (exenatide) injection with insulin glargine in people with type 2 diabetes.
The U.S. Food and Drug Administration announced a final rule establishing regulations to require current good manufacturing practices (cGMP) for dietary supplements.
Galvus (vildagliptin) by Novartis AG (NYSE: NVS), a new once-daily oral treatment for type 2 diabetes submitted for approval in the US and Europe, has been shown in new clinical data to deliver consistent and robust blood sugar reductions in patients with this progressive disease estimated to affect about 246 million people worldwide.
It has long been known that eating potatoes is good for bowel health, but new research suggests that they may also have a beneficial effect on the whole immune system. Especially if eaten cold or in a potato salad, Anne Pichon reports in Chemistry & Industry, the magazine of the SCI.
Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) for INTUNIV (guanfacine) extended release tablets (previously referred to as SPD503), a nonstimulant selective alpha-2A-receptor agonist that has been studied in children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD).
A research team has identified a new biological function for a soccer ball-shaped nanoparticle called a buckyball ? the ability to block allergic response, setting the stage for the development of new therapies for allergy.